Candel Therapeutics, Inc. (CADL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.78-1.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CADL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete pre-BLA readiness activities and submit Biologics License Application for aglatimagene in localized, intermediate- to high-risk prostate cancer by Q4 2026.
Stated as a priority in 3 of last 3 quarters. Management consistently plans to submit the BLA for aglatimagene in localized prostate cancer in Q4 2026. While no revenue is reported, the company is advancing CMC activities and clinical study reports to support this submission. The trajectory is delivering as the company progresses toward this regulatory milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec in localized prostate cancer in Q4 2026.”
“Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec in localized prostate cancer in Q4 2026.”
“Submission of BLA for CAN-2409 in prostate cancer is expected in Q4 2026.”
Advance commercial readiness activities and partnerships to support a potential U.S. launch of aglatimagene in localized prostate cancer in 2027, if approved.
Stated as a priority in 3 of last 3 quarters. Management highlights commercial readiness efforts including partnerships with EVERSANA and IDEA Pharma to support a potential 2027 U.S. launch of aglatimagene. Cash increased from $119.7M at 2025-Q4 to $201.6M at 2026-Q2, supporting operations into Q1 2028. The trajectory is delivering with ongoing commercial preparations and financial capacity.
“We believe we are well-positioned to execute our operating plan including activities intended to support a potential U.S. commercial launch of aglatimagene in 2027, if approved.”
“On the commercial readiness front, we are encouraged by our progress in building a partnership-driven model to support potential U.S. launch of aglatimagene in localized prostate cancer.”
“Positions us to advance key priorities including preparation for a potential commercial launch of aglatimagene.”
Start the global pivotal phase 3 clinical trial (AURORA) of aglatimagene plus valacyclovir in patients with metastatic non-squamous NSCLC in Q2 2026.
Stated as a priority in 3 of last 3 quarters. The company activated the first trial site and opened enrollment for the pivotal phase 3 NSCLC trial in 2026-Q2 as planned. This milestone aligns with management's stated timeline and represents substantive delivery on the clinical development front.
“Activated first trial site and open enrollment for global pivotal phase 3 clinical trial (AURORA) in NSCLC.”
“Plans to initiate a pivotal phase 3 clinical trial of aglatimagene in NSCLC in Q2 2026.”
“The Company plans to initiate a pivotal phase 3 clinical trial of CAN-2409 in NSCLC in Q2 2026.”
Progress next-stage development planning and potential randomized phase 2 dose-regimen-finding trial for linoserpaturev in recurrent glioblastoma.
Stated as a priority in 2 of last 3 quarters. Management is advancing development planning for linoserpaturev in recurrent glioblastoma, including preparation for a potential randomized phase 2 trial. While no revenue or clinical data milestones are reported yet, the company is delivering on regulatory and planning progress.
“Advancing next stage of development planning for linoserpaturev in recurrent glioblastoma with enabling work underway.”
“Received FDA clearance to proceed with IND for linoserpaturev in recurrent high-grade glioma in Q1 2026.”
Begin a pivotal phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) in Q2 2026.
Over the trailing year it converted 2.04x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.